OR WAIT 15 SECS
The 10-year agreement augments Adaptimmune’s license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System for use in the manufacture of Adaptimmune’s SPEAR T-cell therapies.
Adaptimmune Therapeutics announced on June 21, 2016 that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific. The 10-year agreement augments Adaptimmune’s license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System for use in the manufacture of Adaptimmune’s SPEAR T-cell therapies, Adaptimmune said in a press announcement.
Dynabeads CD3/CD28 CTS is designed to isolate, activate, and expand human T-cells.This technology provides coordinated and simultaneous activation and co-stimulation signals to T-cells. This process is reported to produce T-cells with enhanced proliferation and characteristics that enable prolonged persistence in vivo, Adaptimmune noted. Adaptimmune has an exclusive license for the IP associated with the use of Dynabeads CD3/CD28 to expand and activate all TCR-transduced T-cells in cancer, infectious, and autoimmune diseases.
Adaptimmune’s SPEAR T-cell therapies are novel cancer immunotherapies that have been engineered through their T-cell receptors (TCRs) to target and destroy cancer cells by strengthening a patient’s natural T-cell response. The manufacturing process consists of isolating T-cells from the blood of cancer patients, transferring affinity enhanced TCRs, which have been modified to recognize cancer cells, into the cells, activating and expanding the T-cells using Dynabeads CD3/CD28, and introducing the affinity enhanced cells back into the patient to enable the patient's immune system to respond and attack cancer.